SUO 2025 Videos

Reimbursement RVU and Physician Surveys in Urology - Kyle Richards

Analysis of Restructured Grant Evaluation Processes at the NIH - Samuel Washington

Analysis of ctDNA in IMvigor011 Informs Adjuvant Therapy Decisions for Muscle-Invasive Bladder Cancer - Matthew Galsky

Navigating Treatment Options and Trial Designs for Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Vignesh Packiam

CISTO Study: Patient Preferences Drive Bladder Cancer Treatment Choice, Shaping Quality of Life Outcomes - Angela Smith

SunRISe-1 Cohort 4 Analysis: One-Year Disease-Free Survival in BCG-Unresponsive Papillary Bladder Cancer - Siamak Daneshmand

SUO 2025 Session Highlights: Refined Hematuria Guidelines and Expanding Bladder Cancer Trial Landscape - Woodson Smelser

CORE-008 Cohort A First Results on Cretostimogene Grenadenorepvec for BCG-Naive Bladder Cancer - Shane Pearce

Design and Safety of a Patient-Centric Expanded Access Program with Cretostimogene Grenadenorepvec - Sarah Psutka

Subgroup Findings from CREST Trial in High-Risk Bladder Cancer - Gary Steinberg

KEYNOTE-905 Evaluates Perioperative EV+Pembrolizumab in Cisplatin-Ineligible Bladder Cancer - Hristos Kaimakliotis

Phase 1 Study Evaluates Bone Metastasis Resolution with SYNC-T Therapy SV-102 - Gerald Andriole

Coronary Atherosclerosis Findings from the REVELUTION Trial of Leuprolide and Relugolix - Avirup Guha & Sagar Patel

Cohort P Data from the BOND-003 Study in BCG-Unresponsive Papillary Bladder Cancer - Mark Tyson

ZIRCON-X: CAIX PET Imaging and Its Role in Biopsy, Surgery, and Care Planning for Indeterminate Renal Masses - Brian Shuch

24-Month Follow-Up Data from Phase 3 BOND-003 Cohort C Trial - Mark Tyson

CORE-008 Cohort B Investigates Cretostimogene Grenadenorepvec for BCG-Exposed High-Risk NMIBC - Trinity Bivalacqua

SUO 2025 Preview: Bladder Cancer Data from BCG-Unresponsive to Metastatic Disease - Patrick Hensley